Compare CCBG & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCBG | CRMD |
|---|---|---|
| Founded | 1895 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.7M | 509.9M |
| IPO Year | 1994 | 2009 |
| Metric | CCBG | CRMD |
|---|---|---|
| Price | $42.56 | $6.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $45.00 | $14.67 |
| AVG Volume (30 Days) | 73.2K | ★ 1.5M |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | 15.38 | ★ 780.00 |
| EPS | ★ 3.60 | 2.04 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | $6.25 | $1.10 |
| Revenue Next Year | $3.17 | N/A |
| P/E Ratio | $11.73 | ★ $3.16 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $32.38 | $5.60 |
| 52 Week High | $46.83 | $17.43 |
| Indicator | CCBG | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 39.30 |
| Support Level | $41.65 | $6.13 |
| Resistance Level | $44.39 | $7.44 |
| Average True Range (ATR) | 1.13 | 0.30 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 53.74 | 31.18 |
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services, among others, through its banking offices in Florida, Georgia, and Alabama.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.